SCHEMBL3517027

SCHEMBL3517027

CC(C)CN(Cc1ccc2c(c1)OCCO2)C(=O)C1CN(Cc2cn(-c3ccccc3)nc2-c2ccccc2)CCO1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.49
KDM4E B2RXH2 11/20 0.46
ALDH1A1 P00352 10/20 0.46
POLB P06746 3/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518042 0.91 PROKR2 (0.52) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3519737 0.85 PROKR2 (0.51) PROKR2ALDH1A1KMT2AMEN1LMNA
SCHEMBL3521304 0.85 PROKR2 (0.54) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3516502 0.85 PROKR2 (0.57) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3518033 0.84 PROKR2 (0.59) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3520200 0.84 PROKR2 (0.59) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3518041 0.84 PROKR2 (0.59) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3516465 0.83 PROKR2 (0.56) PROKR2KDM4EALDH1A1POLBKMT2A
SCHEMBL3516665 0.83 PROKR2 (0.55) PROKR2KDM4EALDH1A1POLBGAA
SCHEMBL3520561 0.82 PROKR2 (0.56) PROKR2KDM4EALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-A2 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2008-08-27 EP claimed
WO-2007067511-A2 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-06-14 WO claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885KDM4E 4734/4885ALDH1A1 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.